OXIME ETHERS

The invention relates to novel oxime ethers of the general formula /I/ and acid addition salts and quaternary ammonium derivatives thereof, /I/ wherein A represents a C2-6 straight or branched alkylene chain, R and R1 each represent a C1-6 alkyl group or they form together with the adjacent nitrogen...

Full description

Saved in:
Bibliographic Details
Main Authors TIBOR MEZEI, PETER GOROG, ZOLTAN BUDAI, KATALIN GRASSER, ENIKO SZIRT, IBOLYA KOSOCZKY, ARANKA LAY, LUJZA PETOCZ
Format Patent
LanguageEnglish
Published 07.07.1983
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to novel oxime ethers of the general formula /I/ and acid addition salts and quaternary ammonium derivatives thereof, /I/ wherein A represents a C2-6 straight or branched alkylene chain, R and R1 each represent a C1-6 alkyl group or they form together with the adjacent nitrogen atom a heterocyclic ring containing 4 to 7 carbon atoms and optionally a further hetero atom, i.e. an oxygen, sulfur or nitrogen atom, and said ring may be optionally substituted by a C1-3 alkyl, phenyl or benzyl group, R2 and R3 each denote a hydrogen atom or together form a valency bond, R4 denotes a C1-10 alkyl or C2-10 alkenyl group, and n denotes an integer from 3 to 7. The compounds of the general formula /I/ are prepared according to the invention by reacting a cycloalkane derivative of the general formula /II/ /II/ wherein R2, R3, R4 and n have the same meaning as above, whereas Y denotes an oxygen or sulphur atom or a =N-OH group with an aminoalkyl derivative of the general formula /III/ /III/ wherein R, R1 and A have the same meaning as stated above and Z means a halogen atom or a H2N-O- group or a salt thereof in the presence of a basic condensing agent. The new compounds of the general formula /I/ possess valuable nicotine-lethality inhibiting, local anaesthetic, analgesic effects, which are, in case of certain compounds, complemented by anti-hypertensive, maximum electroshock and tetracorspasm inhibiting, ulcus inhibiting and motility inhibiting effects, and can be applied to advantage in the therapy.
Bibliography:Application Number: AU19800060035